[HTML][HTML] QA makes a clinical trial stronger: evidence-based medicine in radiation therapy
DC Weber, M Tomsej, C Melidis… - Radiotherapy and …, 2012 - Elsevier
Quality assurance (QA) for radiation therapy (RT) in clinical trials is necessary to ensure
treatment is safely and effectively administered. QA assurance requires however substantial …
treatment is safely and effectively administered. QA assurance requires however substantial …
A review of methods of analysis in contouring studies for radiation oncology
Inter‐observer variability in anatomical contouring is the biggest contributor to uncertainty in
radiation treatment planning. Contouring studies are frequently performed to investigate the …
radiation treatment planning. Contouring studies are frequently performed to investigate the …
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with …
JW Denham, D Joseph, DS Lamb, NA Spry… - The lancet …, 2019 - thelancet.com
Background The optimal duration of androgen suppression for men with locally advanced
prostate cancer receiving radiotherapy with curative intent is yet to be defined. Zoledronic …
prostate cancer receiving radiotherapy with curative intent is yet to be defined. Zoledronic …
A national repository of complete radiotherapy plans: design, Results, and experiences
Background Previously, many radiotherapy (RT) trials were based on a few selected dose
measures. Many research questions, however, rely on access to the complete dose …
measures. Many research questions, however, rely on access to the complete dose …
Radiation dose escalation or longer androgen suppression to prevent distant progression in men with locally advanced prostate cancer: 10-year data from the TROG …
D Joseph, JW Denham, A Steigler, DS Lamb… - International Journal of …, 2020 - Elsevier
Purpose To clarify the relative effects of duration of androgen suppression (AS) and
radiation dose escalation (RDE) on distant progression (DP) in men with locally advanced …
radiation dose escalation (RDE) on distant progression (DP) in men with locally advanced …
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with …
JW Denham, D Joseph, DS Lamb, NA Spry… - The Lancet …, 2014 - thelancet.com
Background We investigated whether 18 months of androgen suppression plus
radiotherapy, with or without 18 months of zoledronic acid, is more effective than 6 months of …
radiotherapy, with or without 18 months of zoledronic acid, is more effective than 6 months of …
Plan quality in radiotherapy treatment planning–Review of the factors and challenges
A high‐quality treatment plan aims to best achieve the clinical prescription, balancing high
target dose to maximise tumour control against sufficiently low organ‐at‐risk dose for …
target dose to maximise tumour control against sufficiently low organ‐at‐risk dose for …
Quality assurance for prospective EORTC radiation oncology trials: the challenges of advanced technology in a multicenter international setting
DC Weber, PMP Poortmans, CW Hurkmans… - Radiotherapy and …, 2011 - Elsevier
The European Organization for the Research and Treatment of Cancer (EORTC) is a pan-
European structure charged with improving cancer treatment through the testing of new …
European structure charged with improving cancer treatment through the testing of new …
Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer
Introduction Aging skeletal muscle is associated with not only a reduction in muscle size and
strength but also in muscle quality which reflects an increase in fatty infiltration of muscle. In …
strength but also in muscle quality which reflects an increase in fatty infiltration of muscle. In …
Modeling urinary dysfunction after external beam radiation therapy of the prostate using bladder dose-surface maps: evidence of spatially variable response of the …
Purpose We assessed the association of the spatial distribution of dose to the bladder
surface, described using dose-surface maps, with the risk of urinary dysfunction. Methods …
surface, described using dose-surface maps, with the risk of urinary dysfunction. Methods …